drugset / Trial / NCT05640193
A Study of LN-144 in People With Metastatic Melanoma to the Brain
Phase 1
Active not recruiting
10 enrolled
Memorial Sloan Kettering Cancer Center
Iovance Biotherapeutics, Inc. · collabStanford University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.
Timeline
- Start
- 2022-11-25
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |